Drug Trial Radar · NCT07860216
Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25,000
Planned (sponsor's estimate)
Start
Aug 21, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Beijing BeneWill Technology Development Co., LtdAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase III clinical trial with a multicenter, randomized, blinded, placebo-controlled design to evaluate the protective efficacy, safety, and immunogenicity of the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) in individuals aged 60 and above. Sample Size and Trial Grouping: This trial plans to enroll 25,000 trial participants aged ≥60 years (with approximately 30% aged 70 and above), with a relatively balanced gender distribution. Participants of each age group (60-69 years old, ≥70 years old) will be randomly assigned to the trial group and the placebo group in a 1:1 ratio. The sample size for the immunogenicity subgroup is not calculated based on statistical power. Referring to similar clinical trials of RSV vaccines and in conjunction with the immunogenicity observation objectives of this trial, the first 300 trial participants (including those from both age groups) from each site under the leading institution will be included in the immunogenicity subgroup, for a total of 1,200 participants.
Conditions
- Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
Interventions
Recombinant respiratory syncytial virus vaccine (CHO cell)Biological
Test vaccine BW-201 (Adj 1): After mixing the "recombinant respiratory syncytial virus vaccine adjuvant injection" upside down, fully aspirate and inject it into the "RSV vaccine" lyophilized powder for re-dissolution. Slowly rotate the vial to mix, and use it after complete dissolution. After mixing the antigen and adjuvant, store them in a refrigerator at 2°C-8°C in the dark and use them within 4 hours. Before use, they need to be mixed again. If the mixture of antigen and adjuvant is left at room temperature (not exceeding 25°C), it needs to be used within 30 minutes. After mixing 1 bottle of adjuvant solution according to the above steps, aspirate the entire content and add it to the antigen, followed by mixing. Each person should receive 0.5mL per injection, administered intramuscularly into the deltoid muscle on the lateral side of the upper arm. Intravenous injection is strictly prohibited.
Sodium Chloride Injection 0.9%Biological
The placebo is a 0.9% sodium chloride solution. Each person is to receive 0.5mL for intramuscular injection, with the injection site being the deltoid muscle on the lateral side of the upper arm. Intravenous injection is strictly prohibited. The remaining 0.9% sodium chloride solution (approximately 9.5mL) should be disposed of as waste.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).Time frame: From 14 days after vaccination until the end of S1, the evaluation period can last up to 12 months.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Guizhou Provincial Center for Disease Control and Prevention
GuiZhou, Guizhou, China · Recruiting
Hebei Provincial Center for Disease Control and Prevention
Hebei, Hebei, China · Recruiting
Hubei Provincial Center for Disease Control and Prevention
HuBei, Hubei, China · Not yet recruiting
Hunan Province Center for Disease Control and Prevention
HuNan, Hunan, China · Recruiting
Shandong Provincial Center for Disease Control and Prevention
Shandong, Shandong, China · Not yet recruiting
Shaanxi Provincial Center for Disease Control and Prevention
Shanxi, Shanxi, China · Not yet recruiting
Baoshan Second People's Hospital in Yunnan Province
Baoshan, Yunnan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.